Westpac Banking Corp Purchases 40,185 Shares of 10x Genomics $TXG

Westpac Banking Corp acquired a new position in 10x Genomics (NASDAQ:TXG – Free Report) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 40,185 shares of the company’s stock, valued at approximately $3,631,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Sei Investments Co. increased its stake in shares of 10x Genomics by 113.5% during the first quarter. Sei Investments Co. now owns 44,679 shares of the company’s stock valued at $949,000 after purchasing an additional 23,748 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of 10x Genomics during the second quarter valued at approximately $2,069,000. HB Wealth Management LLC bought a new stake in shares of 10x Genomics in the 2nd quarter worth approximately $285,000. Proficio Capital Partners LLC bought a new position in 10x Genomics during the 2nd quarter valued at approximately $781,000. Finally, Counterpoint Mutual Funds LLC bought a new position in 10x Genomics during the 3rd quarter valued at approximately $11,364,000. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have issued reports on TXG shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of 10x Genomics in a research note on Monday, September 21st. Stephens lowered shares of 10x Genomics from an “overweight” rating to an “equal weight” rating in a research note on Friday, October 23rd. TD Cowen upped their price objective on 10x Genomics from $47.00 to $70.00 and gave the company a “hold” rating in a research report on Tuesday, October 13th. Leerink Partners increased their price target on shares of 10x Genomics from $40.00 to $90.00 and gave the stock a “market perform” rating in a research report on Tuesday, September 29th. Finally, Royal Bank Of Canada initiated coverage on shares of 10x Genomics in a research report on Tuesday, September 1st. They set a “sector perform” rating and a $70.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, 10x Genomics has a consensus rating of “Hold” and a consensus price target of $68.40.

View Our Latest Report on TXG

Insider Transactions at 10x Genomics

In related news, Director John R. Stuelpnagel sold 20,000 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $61.75, for a total value of $1,235,000.00. Following the completion of the transaction, the director owned 328,436 shares of the company’s stock, valued at approximately $20,280,923. This trade represents a 5.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Adam Taich sold 46,388 shares of 10x Genomics stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total value of $2,995,273.16. Following the completion of the transaction, the chief financial officer owned 316,344 shares of the company’s stock, valued at approximately $20,426,332.08. This represents a 12.79% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 190,333 shares of company stock worth $12,604,970. 8.84% of the stock is currently owned by corporate insiders.

10x Genomics Price Performance

10x Genomics stock opened at $57.38 on Friday. The stock has a market cap of $7.55 billion, a P/E ratio of -110.35 and a beta of 2.03. 10x Genomics has a 1 year low of $15.18 and a 1 year high of $102.81. The firm’s 50 day moving average price is $73.20 and its 200-day moving average price is $43.29.

10x Genomics (NASDAQ:TXG – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.12. The company had revenue of $150.67 million during the quarter, compared to analyst estimates of $147.96 million. 10x Genomics had a negative return on equity of 8.19% and a negative net margin of 10.84%. The firm’s revenue was up 1.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.22) earnings per share. As a group, equities analysts expect that 10x Genomics will post -0.67 EPS for the current year.

10x Genomics Company Profile

(Free Report)

10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.

Read More

Institutional Ownership by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.